Cargando…

Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?

Over the past few decades, extensive research has shed light on immune alterations and the significance of dysfunctional biological barriers in psychiatric disorders. The leaky gut phenomenon, intimately linked to the integrity of both brain and intestinal barriers, may play a crucial role in the or...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín-Hernández, David, Muñoz-López, Marina, Tendilla-Beltrán, Hiram, Caso, Javier R., García-Bueno, Borja, Menchén, Luis, Leza, Juan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454107/
https://www.ncbi.nlm.nih.gov/pubmed/37628815
http://dx.doi.org/10.3390/ijms241612634
_version_ 1785096107879038976
author Martín-Hernández, David
Muñoz-López, Marina
Tendilla-Beltrán, Hiram
Caso, Javier R.
García-Bueno, Borja
Menchén, Luis
Leza, Juan C.
author_facet Martín-Hernández, David
Muñoz-López, Marina
Tendilla-Beltrán, Hiram
Caso, Javier R.
García-Bueno, Borja
Menchén, Luis
Leza, Juan C.
author_sort Martín-Hernández, David
collection PubMed
description Over the past few decades, extensive research has shed light on immune alterations and the significance of dysfunctional biological barriers in psychiatric disorders. The leaky gut phenomenon, intimately linked to the integrity of both brain and intestinal barriers, may play a crucial role in the origin of peripheral and central inflammation in these pathologies. Sphingosine-1-phosphate (S1P) is a bioactive lipid that regulates both the immune response and the permeability of biological barriers. Notably, S1P-based drugs, such as fingolimod and ozanimod, have received approval for treating multiple sclerosis, an autoimmune disease of the central nervous system (CNS), and ulcerative colitis, an inflammatory condition of the colon, respectively. Although the precise mechanisms of action are still under investigation, the effectiveness of S1P-based drugs in treating these pathologies sparks a debate on extending their use in psychiatry. This comprehensive review aims to delve into the molecular mechanisms through which S1P modulates the immune system and brain/intestinal barrier functions. Furthermore, it will specifically focus on psychiatric diseases, with the primary objective of uncovering the potential of innovative therapies based on S1P signaling.
format Online
Article
Text
id pubmed-10454107
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104541072023-08-26 Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm? Martín-Hernández, David Muñoz-López, Marina Tendilla-Beltrán, Hiram Caso, Javier R. García-Bueno, Borja Menchén, Luis Leza, Juan C. Int J Mol Sci Review Over the past few decades, extensive research has shed light on immune alterations and the significance of dysfunctional biological barriers in psychiatric disorders. The leaky gut phenomenon, intimately linked to the integrity of both brain and intestinal barriers, may play a crucial role in the origin of peripheral and central inflammation in these pathologies. Sphingosine-1-phosphate (S1P) is a bioactive lipid that regulates both the immune response and the permeability of biological barriers. Notably, S1P-based drugs, such as fingolimod and ozanimod, have received approval for treating multiple sclerosis, an autoimmune disease of the central nervous system (CNS), and ulcerative colitis, an inflammatory condition of the colon, respectively. Although the precise mechanisms of action are still under investigation, the effectiveness of S1P-based drugs in treating these pathologies sparks a debate on extending their use in psychiatry. This comprehensive review aims to delve into the molecular mechanisms through which S1P modulates the immune system and brain/intestinal barrier functions. Furthermore, it will specifically focus on psychiatric diseases, with the primary objective of uncovering the potential of innovative therapies based on S1P signaling. MDPI 2023-08-10 /pmc/articles/PMC10454107/ /pubmed/37628815 http://dx.doi.org/10.3390/ijms241612634 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Martín-Hernández, David
Muñoz-López, Marina
Tendilla-Beltrán, Hiram
Caso, Javier R.
García-Bueno, Borja
Menchén, Luis
Leza, Juan C.
Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?
title Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?
title_full Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?
title_fullStr Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?
title_full_unstemmed Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?
title_short Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?
title_sort immune system and brain/intestinal barrier functions in psychiatric diseases: is sphingosine-1-phosphate at the helm?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454107/
https://www.ncbi.nlm.nih.gov/pubmed/37628815
http://dx.doi.org/10.3390/ijms241612634
work_keys_str_mv AT martinhernandezdavid immunesystemandbrainintestinalbarrierfunctionsinpsychiatricdiseasesissphingosine1phosphateatthehelm
AT munozlopezmarina immunesystemandbrainintestinalbarrierfunctionsinpsychiatricdiseasesissphingosine1phosphateatthehelm
AT tendillabeltranhiram immunesystemandbrainintestinalbarrierfunctionsinpsychiatricdiseasesissphingosine1phosphateatthehelm
AT casojavierr immunesystemandbrainintestinalbarrierfunctionsinpsychiatricdiseasesissphingosine1phosphateatthehelm
AT garciabuenoborja immunesystemandbrainintestinalbarrierfunctionsinpsychiatricdiseasesissphingosine1phosphateatthehelm
AT menchenluis immunesystemandbrainintestinalbarrierfunctionsinpsychiatricdiseasesissphingosine1phosphateatthehelm
AT lezajuanc immunesystemandbrainintestinalbarrierfunctionsinpsychiatricdiseasesissphingosine1phosphateatthehelm